Jolanda De Vries - Selected Publications#

Researcher ID: F-5563-2010
Records in Pubmed: 198
Web of science H Index: 56
Number of times cited: 10.468 (9.549 without self citations)

Professor De Vries has heavily invested in the translation of laboratory discoveries into clinical application with potential benefit for cancer patients. The first three selected papers are describing academic-initiated clinical trials with medicinal cellular products developed by De Vries.

1. Westdorp, H, Creemers, JHA, van Oort, IM, Schreibelt, G, Gorris, MAJ, Mehra, N, Simons, M, de Goede, AL, van Rossum, MM, Croockewit, AJ, Figdor, CG, Witjes, JA, Aarntzen, E, Mus, RDM, Bruning, M, Petry, K, Gotthardt, M, Barentsz, JO, de Vries, IJM, Gerritsen, WR. Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancer. J Immunother Cancer, 2019: 302. IF 10.252, citations 9

In this paper, the worldwide first trial with naturally occuring dendritic cell subtypes in prostate cancer is presented showing the potency of thess cell types in combating cancer.

2. Schreibelt, G, Bol, KF, Westdorp, H, Wimmers, F, Aarntzen, EHJG, Duiveman-de Boer, T, van de Rakt, MWMM, Scharenborg, NM, De Boer, AJ, Pots, JM, Nordkamp, MAMO, van Oorschot, TGM, Tel, J, Winkels, G, Petry, K, Blokx, WAM, van Rossum, MM, Welzen, MEB, Mus, RDM, Croockewit, SAJ, Koornstra, RHT, Jacobs, JFM, Kelderman, S, Blank, CU, Gerritsen, WR, Punt, CJA, Figdor, CG, de Vries, IJM. Effective Clinical Responses in Metastatic Melanoma Patients after Vaccination with Primary Myeloid Dendritic Cells. Clinical Cancer Research, 2016: 2155-2166. IF 10.107, citations 106

Here, the potency of the myeloid subset of blood-derived dendritic cells in combating cancer is presented. The remarkable good clinical results with these naturally occuring subsets solely, led to the very novel approach to combine the subsets, a strategy currently being tested in the phase 3 trial financed by the Dutch government.

3. Bol, KF, van den Bosch, T, Schreibelt, G, Mensink, HW, Keunen, JE, Kilic, E, Japing, WJ, Geul, KW, Westdorp, H, Boudewijns, S, Croockewit, SA, van Rossum, MM, de Goede, AL, Naus, NC, van der Graaf, WT, Gerritsen, WR, de Klein, A, Punt, CJ, Figdor, CG, Cohen, VM, Paridaens, D, de Vries, IJ. Adjuvant Dendritic Cell Vaccination in High-Risk Uveal Melanoma. Ophthalmology, 2016: 2265-7. IF 8.470, citations 15

This paper, published in the highest journal for Ophthalmologists, shows that the approach developed by De Vries is most effective in patients at risk to develop cancer. In this study, patients that underwent surgery were successfully vaccinated to prevent relapse. The paper showing vaccination in a preventive setting is not yet accepted.

Imaging and immunomonitoring:

Already right from the start of her DC trials, De Vries recognised that next to measuring effects on the tumour, monitoring the behaviour of the cellular vaccine and measuring immune responses is of utmost importance. She developed a toolbox of techniques to measure and visualize immune processes in vivo and in vitro, thus developing also novel theranostics. She expects that this spin-off technology will not be limited to oncology, but be helpful to advance personalized healthcare in general.

4. Aarntzen EH, Srinivas M, De Wilt JH, Jacobs JF, Lesterhuis WJ, Windhorst AD, Troost EG, Bonenkamp JJ, van Rossum MM, Blokx WA, Mus RD, Boerman OC, Punt CJ, Figdor CG, Oyen WJ, de Vries IJ. Early identification of antigen-specific immune responses in vivo by [18F]]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]]FLT) PET imaging. Proc Natl Acad Sci USA, 2011: 18396-9. IF 9.412, citations 45

Here, Jolanda de Vries published a very useful technique to identify immunological responding patients. She collaborated with experts in the field of Nuclear Medicine to employ this innovative technique.

5. de Vries IJ, Lesterhuis WJ, Barentsz JO, Verdijk P, van Krieken JH, Boerman OC, Oyen WJ, Bonenkamp JJ, Boezeman JB, Adema GJ, Bulte JW, Scheenen TW, Punt CJ, Heerschap A, Figdor CG. Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. Nat Biotechnol, 2005: 1407-13. IF 36.553, citations 636

This highly cited paper is De Vries most recognised innovation in the field of Molecular Imaging and led to many invitations at renowned conferences.

6. Vasaturo, A, Halilovic, A, Bol, KF, Verweij, DI, Blokx, WA, Punt, CJ, Groenen, PJ, van Krieken, JH, Textor, J, de Vries, IJ, Figdor, CG. T-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines. Cancer Res, 2016: 3496-506. IF 9.727, citations 19

This paper describes the discovery of the importance of immune cells present in tumors years before cellular therapy is initiated.

Fundamental:

To stay at the forefront of translational research it is of the utmost importance to continuously fuel the pipeline for the next implementation. For a next generation of dendritic cell vaccines, a better understanding of the function and potential synergism of subtypes of natural circulating DC is necessary. De Vries envisages to reach this goal by maximally exploiting her knowledge on fundamental biology of dendritic cells. Therefore, her laboratory is constantly searching for new avenues to make superior vaccines for the benefit of (cancer) patients.

7. Benitez-Ribas D, Adema GJ, Winkels G, Klasen IS, Punt CJ, Figdor CG, de Vries IJ. Plasmacytoid dendritic cells of melanoma patients present exogenous proteins to CD4+ T cells after Fc gamma RII-mediated uptake. J Exp Med, 2006: 1629-35. IF 11.743, citations 83

8. Tel J, Schreibelt G, Sittig SP, Mathan TS, Buschow SI, Cruz LJ, Lambeck AJ, Figdor CG, de Vries IJ. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood, 2013: 459-67. IF 17.794, citations 99

9. Wimmers, F, Subedi, N, van Buuringen, N, Heister, D, Vivie, J, Beeren-Reinieren, I, Woestenenk, R, Dolstra, H, Piruska, A, Jacobs, JFM, van Oudenaarden, A, Figdor, CG, Huck, WTS, de Vries, IJM, Tel, J. Single-cell analysis reveals that stochasticity and paracrine signaling control interferon-alpha production by plasmacytoid dendritic cells. Nat Commun, 2018: 3317. IF 12.121, citations 36

The above-mentioned papers were the first to show the uptake, (cross)-presentation of antigens, and the tightly controlled interferon-alpha production by human plasmacytoid dendritic cells. Here De Vries proves that this DC subset is suitable as a cancer vaccine. Till that moment they were thought to be detrimental for cancer. These papers formed the rationale for the clinical trials with this cell type.

10. Bakdash, G, Buschow, SI, Gorris, MA, Halilovic, A, Hato, SV, Skold, AE, Schreibelt, G, Sittig, SP, Torensma, R, Duiveman-de Boer, T, Schroder, C, Smits, EL, Figdor, CG, de Vries, IJ. Expansion of a BDCA1+CD14+ Myeloid Cell Population in Melanoma Patients May Attenuate the Efficacy of Dendritic Cell Vaccines. Cancer Res, 2016: p. 4332-46. IF 9.727, citations 42

In this paper, a subset of suppressive cells was identified in cancer patients. This led to the discovery that in cancer patients, dendritic cells can become suppressive. Hence, the vaccine production procedure was adapted: Removal of suppressive cells before injection into patients. This should lead to enhanced immunity against tumours.